中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (10): 741-746.doi: 10.12144/zgmfskin202210741

• 综述 • 上一篇    下一篇

单纯型大疱性表皮松解症治疗研究进展

王华1,唐嘉键2,申玲1,宋燕1   

  1. 1广州领晟医疗科技有限公司，广州，510663;
    2清华大学药学院，北京，100084
  • 出版日期:2022-10-15 发布日期:2022-08-23

Research progress in treatment of epidermolysis bullosa simplex

WANG Hua1, TANG Jiajian2, SHEN Ling1, SONG Yan1   

  1. 1 Guangzhou Link Health Pharma Co. Ltd, Guangzhou 510663,China;2 School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084,China
  • Online:2022-10-15 Published:2022-08-23

PDF (PC)

234

摘要： 单纯型大疱性表皮松解症（EB）是一类罕见的遗传性皮肤病，目前治疗以改善患者生活质量的对症治疗为主，包括抗炎、止痒、止汗等药物治疗方向，另应用间充质干细胞、诱导性多能干细胞移植以及转录激活因子样效应物核酸酶、CRISPER/Cas9等技术的相关治疗手段取得了很大进展。

关键词: 单纯型大疱性表皮松解症, 遗传性皮肤病, 角蛋白, Oleogel-S10, 双醋瑞因

Abstract: Epidermolysis bullosa simplex is a rare genodermatosis. The current treatment focused on symptom-relieved therapies, including anti-inflammation, antipruritic and antiperspirant, and other treatments including mesenchymal stem cell, implantation of pluripotent stem cells and transcription activator-like effector nuclease, CRISPER/Cas9. The update of the treatments of epidermolysis bullosa is reviewed in this paper.

Key words: epidermolysis bullosa simplex, genodermatosis, keratin, Oleogel-S10, Diacerein